Bavarian Nordic Cash Flow Conversion Efficiency
Bavarian Nordic cash flow conversion efficiency. Based on the latest financial reports, Bavarian Nordic (BAVA) has a cash flow conversion efficiency ratio of 0.042x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr545.05 Million ≈ $85.28 Million USD) by net assets (Dkr12.87 Billion ≈ $2.01 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Bavarian Nordic for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Bavarian Nordic (2001–2025)
Cash flow conversion efficiency of Bavarian Nordic from 2001 to 2025. This chart illustrates how Bavarian Nordic's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BAVA share price today for real-time trading data and today's change.
Bavarian Nordic Cash Flow Conversion Ratio Explained
Bavarian Nordic cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Bavarian Nordic Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bavarian Nordic ranked by their cash flow conversion efficiency. Review BAVA free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ERMENEGILDO ZEG.DL -0001
F:JN0
|
N/A |
|
First BanCorp
F:OLWN
|
0.072x |
|
Relay Therapeutics Inc
NASDAQ:RLAY
|
-0.080x |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
0.004x |
|
China South Publishing & Media Group Co Ltd
SHG:601098
|
-0.022x |
|
Hypera S.A
SA:HYPE3
|
0.028x |
|
L&K Engineering Suzhou Co Ltd
SHG:603929
|
0.248x |
|
TIZA Information Industry Corporation Inc
SHE:300209
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Bavarian Nordic (2001–2025)
The table below shows the annual cash flow conversion efficiency of Bavarian Nordic from 2001 to 2025. Also see Bavarian Nordic asset portfolio for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Dkr12.87 Billion ≈ $2.01 Billion |
Dkr2.72 Billion ≈ $425.86 Million |
0.211x | +23.74% |
| 2024-12-31 | Dkr11.41 Billion ≈ $1.78 Billion |
Dkr1.95 Billion ≈ $305.07 Million |
0.171x | +57.90% |
| 2023-12-31 | Dkr10.34 Billion ≈ $1.62 Billion |
Dkr1.12 Billion ≈ $175.11 Million |
0.108x | +251.70% |
| 2022-12-31 | Dkr7.15 Billion ≈ $1.12 Billion |
Dkr220.05 Million ≈ $34.43 Million |
0.031x | +163.31% |
| 2021-12-31 | Dkr7.37 Billion ≈ $1.15 Billion |
Dkr-358.50 Million ≈ $-56.09 Million |
-0.049x | -141.60% |
| 2020-12-31 | Dkr4.89 Billion ≈ $765.76 Million |
Dkr571.91 Million ≈ $89.48 Million |
0.117x | +179.00% |
| 2019-12-31 | Dkr1.87 Billion ≈ $291.86 Million |
Dkr-275.91 Million ≈ $-43.17 Million |
-0.148x | -11.78% |
| 2018-12-31 | Dkr2.18 Billion ≈ $341.18 Million |
Dkr-288.53 Million ≈ $-45.14 Million |
-0.132x | -253.48% |
| 2017-12-31 | Dkr2.51 Billion ≈ $392.13 Million |
Dkr216.06 Million ≈ $33.80 Million |
0.086x | -35.01% |
| 2016-12-31 | Dkr2.02 Billion ≈ $315.61 Million |
Dkr267.60 Million ≈ $41.87 Million |
0.133x | +69.09% |
| 2015-12-31 | Dkr1.34 Billion ≈ $210.04 Million |
Dkr105.32 Million ≈ $16.48 Million |
0.078x | -71.00% |
| 2014-12-31 | Dkr1.25 Billion ≈ $195.90 Million |
Dkr338.75 Million ≈ $53.00 Million |
0.271x | +79.58% |
| 2013-12-31 | Dkr976.29 Million ≈ $152.75 Million |
Dkr147.08 Million ≈ $23.01 Million |
0.151x | +649.29% |
| 2012-12-31 | Dkr999.68 Million ≈ $156.41 Million |
Dkr20.10 Million ≈ $3.14 Million |
0.020x | +106.47% |
| 2011-12-31 | Dkr1.21 Billion ≈ $188.94 Million |
Dkr-375.24 Million ≈ $-58.71 Million |
-0.311x | -4.99% |
| 2010-12-31 | Dkr810.43 Million ≈ $126.80 Million |
Dkr-239.86 Million ≈ $-37.53 Million |
-0.296x | +56.95% |
| 2009-12-31 | Dkr704.21 Million ≈ $110.18 Million |
Dkr-484.14 Million ≈ $-75.75 Million |
-0.687x | -3214.05% |
| 2008-12-31 | Dkr1.02 Billion ≈ $158.82 Million |
Dkr22.41 Million ≈ $3.51 Million |
0.022x | -83.52% |
| 2007-12-31 | Dkr1.22 Billion ≈ $190.51 Million |
Dkr163.16 Million ≈ $25.53 Million |
0.134x | +147.63% |
| 2006-12-31 | Dkr691.40 Million ≈ $108.17 Million |
Dkr-194.49 Million ≈ $-30.43 Million |
-0.281x | -204.50% |
| 2005-12-31 | Dkr630.10 Million ≈ $98.58 Million |
Dkr-58.21 Million ≈ $-9.11 Million |
-0.092x | +61.98% |
| 2004-12-31 | Dkr315.39 Million ≈ $49.35 Million |
Dkr-76.63 Million ≈ $-11.99 Million |
-0.243x | -40386.52% |
| 2003-12-31 | Dkr347.00 Million ≈ $54.29 Million |
Dkr209.27K ≈ $32.74K |
0.001x | +100.86% |
| 2002-12-31 | Dkr196.44 Million ≈ $30.73 Million |
Dkr-13.71 Million ≈ $-2.15 Million |
-0.070x | +96.69% |
| 2001-12-31 | Dkr44.14 Million ≈ $6.91 Million |
Dkr-93.12 Million ≈ $-14.57 Million |
-2.109x | -- |
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an or… Read more